Boston Scientific announced a $14.5 billion agreement to acquire Penumbra, a maker of thrombectomy and embolization devices, aiming to expand into fast‑growing vascular and clot‑removal markets. The cash‑and‑stock purchase is intended to broaden Boston Scientific’s urology and vascular portfolios and add Penumbra’s interventional thrombectomy assets and embolization systems. Company executives said the acquisition will accelerate entry into thrombectomy segments where demand for minimally invasive clot‑removal therapies is rising. The transaction is subject to customary approvals and is expected to close in 2026.